RecruitingPhase 3NCT05972551
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Studying Osteogenesis imperfecta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MD, MDAmgen
- Intervention
- Romosozumab(drug)
- Enrollment
- 106 enrolled
- Eligibility
- 5-17 years · All sexes
- Timeline
- 2024 – 2027
Study locations (20)
- Childrens Hospital of Alabama, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- University of California, Los Angeles Interventional Clinical Trials, Los Angeles, California, United States
- Nemours Hospital for Children, Wilmington, Delaware, United States
- Nemours Childrens Hospital, Orlando, Florida, United States
- University of South Florida - Carol and Frank Morsani Center for Advanced Health Care, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Indiana University, Indianapolis, Indiana, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Boston Childrens Hospital, Boston, Massachusetts, United States
- Mayo Clinic Childrens Center, Rochester, Minnesota, United States
- Gillette Childrens Hospital and Clinic Saint Paul, Saint Paul, Minnesota, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Marshfield Clinic, Marshfield, Wisconsin, United States
- Monash Childrens Hospital, Clayton, Victoria, Australia
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05972551 on ClinicalTrials.govOther trials for Osteogenesis imperfecta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07366086Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaAmgen
- RECRUITINGPHASE2NCT07062588Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)Angitia Incorporated Limited
- RECRUITINGNANCT07412782REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)Meyer Children's Hospital IRCCS
- RECRUITINGNANCT07478224An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type IUniversity Hospital, Ghent
- RECRUITINGNCT07287241Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis ImperfectaIstituto Ortopedico Rizzoli
- ACTIVE NOT RECRUITINGPHASE3NCT06636071Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc
- RECRUITINGNANCT05927389Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis ImperfectaUniversity Hospital, Toulouse
- ACTIVE NOT RECRUITINGPHASE3NCT05768854Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc